Yang Lu, Song Mei-qing, Zhang Qiu-ling, Shou Lan, Zang Shu-fei, Yang Yan-li
Department of Endocrinolgy,Affliated Hospital of Hangzhou Normal University,Hangzhou 310015,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Jun;36(3):309-12. doi: 10.3881/j.issn.1000-503X.2014.03.015.
To compare the effects of piglitazone and metformin on retinol-binding protein-4 (RBP-4) and adiponcetin (APN) in patients with type 2 diabetes mellitus (T2DM) complicated with Non alcohol fatty acid liver disease (NAFLD).
Totally 60 T2DM patients complicated with NAFLD were equally and randomly divided into pioglitazone group and metform group. The levels of biochemical indicators including body mass index (BMI), glucose hemoglobin A1C (GHbA1C), insulin resistance (HOMA-IR), fasting blood glucose (FBG), fasting insulin (FIns), and serum triglycerides (TG) as well as serum RBP-4 and APN level were measured pre-treatment and 12 weeks after treatments.
After 12 weeks of treaments, BMI, FBG, HOMA-IR, GHbA1C, FIns, and TG decreased (all P<0.05) in both piglitazone group and metform group. APN increased (all P<0.05) in both groups. RBP-4 decreased (P<0.05) in piglitazone group. Compare with the metform group, the levels of RBP-4, FIns ,and HOMA-IR decreased and BMI increased in piglitazone group (P<0.05).
Piglitazone is superior to metoform in decreasing RBP-4 level and HOMA-IR in patients with T2DM complicated with NAFLD.
比较吡格列酮与二甲双胍对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者视黄醇结合蛋白4(RBP - 4)和脂联素(APN)的影响。
将60例T2DM合并NAFLD患者平均随机分为吡格列酮组和二甲双胍组。在治疗前及治疗12周后测量包括体重指数(BMI)、糖化血红蛋白A1C(GHbA1C)、胰岛素抵抗(HOMA - IR)、空腹血糖(FBG)、空腹胰岛素(FIns)、血清甘油三酯(TG)等生化指标以及血清RBP - 4和APN水平。
治疗12周后,吡格列酮组和二甲双胍组的BMI、FBG、HOMA - IR、GHbA1C、FIns和TG均降低(均P<0.05)。两组的APN均升高(均P<0.05)。吡格列酮组的RBP - 4降低(P<0.05)。与二甲双胍组相比,吡格列酮组的RBP - 4、FIns和HOMA - IR水平降低,BMI升高(P<0.05)。
在降低T2DM合并NAFLD患者的RBP - 4水平和HOMA - IR方面,吡格列酮优于二甲双胍。